These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11673691)

  • 1. Antisense therapeutics: lessons from early clinical trials.
    Flaherty KT; Stevenson JP; O'Dwyer PJ
    Curr Opin Oncol; 2001 Nov; 13(6):499-505. PubMed ID: 11673691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase.
    Monia BP; Johnston JF; Geiger T; Muller M; Fabbro D
    Nat Med; 1996 Jun; 2(6):668-75. PubMed ID: 8640558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
    Moreira JN; Santos A; Simões S
    Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
    Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antisense therapy in oncology: new hope for an old idea?
    Tamm I; Dörken B; Hartmann G
    Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
    Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
    Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
    Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.
    Coudert B; Anthoney A; Fiedler W; Droz JP; Dieras V; Borner M; Smyth JF; Morant R; de Vries MJ; Roelvink M; Fumoleau P;
    Eur J Cancer; 2001 Nov; 37(17):2194-8. PubMed ID: 11677106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense cancer therapy: the state of the science.
    Kushner DM; Silverman RH
    Curr Oncol Rep; 2000 Jan; 2(1):23-30. PubMed ID: 11122821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 antisense therapy in B-cell malignant proliferative disorders.
    Chanan-Khan A; Czuczman MS
    Curr Treat Options Oncol; 2004 Aug; 5(4):261-7. PubMed ID: 15233903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
    Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
    Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells.
    Wang J; Liu X; Jiang W
    Chin Med J (Engl); 2000 Oct; 113(10):957-60. PubMed ID: 11775848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense candidates against protein kinase C-alpha designed based on phylogenesis and simulant structure of mRNA.
    Song HF; Tang ZM; Yuan SJ; Zhu BZ; Liu XW
    Acta Pharmacol Sin; 2003 Mar; 24(3):269-76. PubMed ID: 12617778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense approaches for the treatment of cancer.
    Monia BP; Holmlund J; Dorr FA
    Cancer Invest; 2000; 18(7):635-50. PubMed ID: 11036471
    [No Abstract]   [Full Text] [Related]  

  • 20. Technology evaluation: LErafAON, NeoPharm.
    Moreira JN; Simões S
    Curr Opin Mol Ther; 2003 Oct; 5(5):547-52. PubMed ID: 14601525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.